Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANOPY-2: canakinumab + docetaxel versus placebo + docetaxel in previously treated advanced NSCLC
NL-OMON49205Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of canakinumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Novartis. Primary endpoints: Recommended Phase 3 dose regimen and Overall survival. Started Aug 2019; status: active, not recruiting.
02
Drugs
canakinumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON49205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49205.